Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
Open Access
- 1 August 2008
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 112 (3) , 610-618
- https://doi.org/10.1182/blood-2008-01-135319
Abstract
CD4+CD25highFoxP3+ regulatory T (Treg) cells limit antigen-specific immune responses and are a cause of suppressed anticancer immunity. In preclinicaKeywords
This publication has 27 references indexed in Scilit:
- IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunityBlood, 2007
- Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral toleranceSeminars in Immunology, 2004
- Immunoregulatory T cells in tumor immunityCurrent Opinion in Immunology, 2004
- CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide VaccinationThe Journal of Immunology, 2003
- Increase of regulatory T cells in the peripheral blood of cancer patients.2003
- CD4+CD25+ suppressor T cells: more questions than answersNature Reviews Immunology, 2002
- Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell ProliferationThe Journal of Immunology, 2002
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation toleranceImmunological Reviews, 2001
- Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2001